[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版) . 临床肝胆病杂志, 2019, 35: 2648-2669.
[2] Higashi T , Friedman S L , Hoshida Y . Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev, 2017, 121:27-42.
[3] 胡锡琪. 肝穿刺活组织检查是评估肝纤维化的金标准吗?.中华肝脏病杂志, 2012, 20:568-570.
[4] 王晶晶,陈国凤.无创肝纤维化诊断研究进展.肝脏,2018,23:72-76.
[5] Neuman M G,Cohen L B,Nanau R M. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem, 2016, 49:302-315.
[6] Parsian H,Rahimipour A,Nouri M,et al.Serum hyaluronic acid and laminin as biomarkers in liver fibrosis. J Gastrointestin Liver Dis, 2010, 19:169-174.
[7] 杜静华,南月敏. 肝纤维化新型分子诊断标志物. 临床肝胆病杂志, 2017,33:445-450.
[8] Shaheen A A,Wan A F,Myers R P.FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol, 2007, 102:2589-2600.
[9] 王春妍, 程晓静, 孟超,等. Fibrotest对慢性乙型肝炎肝纤维化程度诊断效能的评估价值.中华肝脏病杂志, 2015, 23:738-741.
[10] 程晓静,陆伟,侯伟,等. FibroTest联合FibroScan对慢性乙型肝炎肝纤维化的诊断价值.临床肝胆病杂志, 2014, 30:424-427.
[11] Salkic N N, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol, 2014, 109:796-809.
[12] Liu D P,Lu W,Zhang Z Q,et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat, 2018,25:581-589.
[13] 徐燕,冯艳玲,施裕新.瞬时弹性成像在慢性乙型肝炎肝纤维化诊断中的应用. 山东医药, 2014,54:21-24.
[14] 代倩,李晶晶,马双双,等.瞬时弹性成像联合APRI和FIB-4指数模型无创诊断慢性HBV感染者肝纤维化的临床价值.安徽医科大学学报, 2017, 52:430-434.
[15] Kim W R, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol, 2016, 64:773-780.
[17] 俞冲,李民,顾玉玲,等.APRI、FIB-4及Fibro Touch联合检测对乙肝肝纤维化的早期预警价值.肝脏, 2018,23:22-25.
[18] Li Y, Chen Y, Zhao Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis. PLoS One,2014,9: e105728.
[16] Xiao G,Yang J,Yan L.Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.Hepatology, 2015, 61: 292-302.
[19] Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases. Cell proliferation, 2018,52:e12538.
[20] Yao M, Wang L, You H, et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B.Clin Chim Acta, 2019, 493: 92-97.
[21] 杨颖,肖蕾,毛睿,等.高尔基体糖蛋白73的表达特征及其对肝癌与肝硬化的鉴别诊断价值.中华肝脏病杂志, 2012,20:920-924.
[22] 姚明解,王雷婕,关贵文,等.血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用. 临床肝胆病杂志, 2018,34:755-759.
[23] Huang H, Wu T, Mao J, et al. CHI3L1 is a liver-enriched,noninvasive biomarker that can be used to stage and diagnose substantial hepatic fibrosis. OMICS, 2015, 19: 339-345.
[24] 李洪,严桐,朱珍, 等.血清壳多糖酶3样蛋白1在慢性肝病显著纤维化和肝硬化中的诊断价值. 中华肝脏病杂志, 2018, 6:337-341.
[25] Li W , Zhu C , Wu Y , et al. Increased P ygo2 expression in liver of patients with hepatitis B virus‐related fibrosis. Liver Int, 2016, 35:2522-2529.
[26] 秦文英, 吕林月, 周策凡,等. Pygo2蛋白在肿瘤中作用机制的研究进展. 世界华人消化杂志, 2016,24:70-76.
[27] 张占卿, 陆伟, 丁荣蓉, 等. 血清HBsAg、HBcrAg和HBV DNA预测慢性乙型肝炎肝组织病理状态的性能评价. 肝脏, 2016, 21:810-818.
[28] Singh S , Muir AJ , Dieterich DT , et al. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology, 2017, 152:1544-1577.
[29] Takemoto R, Nakamuta M, Aoyagi Y, et al. Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Digest Dis, 2010, 10:145-148. |
